CTSO Cytosorbents Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTSO

Price (delayed)

$3.27

Market cap

$142.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

$137.09M

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the ...

Highlights
CTSO's net income is down by 34% year-on-year but it is up by 21% since the previous quarter
CTSO's EPS is down by 32% YoY but it is up by 22% from the previous quarter
The equity has declined by 43% year-on-year and by 10% since the previous quarter
The debt has increased by 39% since the previous quarter and by 37% year-on-year
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cytosorbents.com
Peers: HOLX NEPH BSX

Key stats

What are the main financial stats of CTSO
Market
Shares outstanding
43.66M
Market cap
$142.78M
Enterprise value
$137.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.03
Price to sales (P/S)
4.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.95
Earnings
Revenue
$34.69M
EBIT
-$34.04M
EBITDA
-$32.91M
Free cash flow
-$34.32M
Per share
EPS
-$0.75
Free cash flow per share
-$0.79
Book value per share
$0.81
Revenue per share
$0.8
TBVPS
$1.45
Balance sheet
Total assets
$63.23M
Total liabilities
$27.86M
Debt
$18.14M
Equity
$35.37M
Working capital
$24.05M
Liquidity
Debt to equity
0.51
Current ratio
3.48
Quick ratio
3.04
Net debt/EBITDA
0.17
Margins
EBITDA margin
-94.9%
Gross margin
59.8%
Net margin
-94.6%
Operating margin
-90.9%
Efficiency
Return on assets
-46.9%
Return on equity
-73.9%
Return on invested capital
-81.2%
Return on capital employed
-63.6%
Return on sales
-98.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-3.82%
1 week
1.55%
1 month
-0.3%
1 year
7.92%
YTD
110.97%
QTD
110.97%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$34.69M
Gross profit
$20.73M
Operating income
-$31.52M
Net income
-$32.81M
Gross margin
59.8%
Net margin
-94.6%
Cytosorbents's operating margin has shrunk by 72% YoY but it has increased by 6% QoQ
The net margin has dropped by 66% year-on-year but it has increased by 17% since the previous quarter
CTSO's operating income is down by 39% year-on-year but it is up by 9% since the previous quarter
The gross profit has declined by 35% year-on-year and by 8% since the previous quarter

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
4.03
P/S
4.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.95
CTSO's EPS is down by 32% YoY but it is up by 22% from the previous quarter
CTSO's P/B is 102% higher than its last 4 quarters average of 2.0 but 64% lower than its 5-year quarterly average of 11.1
The equity has declined by 43% year-on-year and by 10% since the previous quarter
The stock's price to sales (P/S) is 71% more than its last 4 quarters average of 2.4 but 50% less than its 5-year quarterly average of 8.3
Cytosorbents's revenue has decreased by 20% YoY and by 3.9% QoQ

Efficiency

How efficient is Cytosorbents business performance
The ROE has plunged by 114% YoY but it has grown by 9% from the previous quarter
The ROA has shrunk by 77% YoY but it has increased by 13% QoQ
CTSO's ROS has plunged by 67% YoY but it is up by 16% from the previous quarter
The ROIC has grown by 25% from the previous quarter and by 7% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The company's total assets is 127% higher than its total liabilities
The company's total assets fell by 29% YoY
The quick ratio is down by 29% YoY but it is up by 5% QoQ
The debt is 49% smaller than the equity
The debt to equity has soared by 143% year-on-year and by 55% since the previous quarter
The equity has declined by 43% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.